Live feed10:05:00·1425dPRReleasevia QuantisnowViiV Healthcare Announces New Data at AIDS 2022 From Unblinded Phase of HPTN 084 Study in Women in Sub-Saharan Africa Showing Continued Superior Efficacy of Injectable Cabotegravir Long-Acting for PrEP Over Daily, Oral TDF/FTC TabletsByQuantisnow·Wall Street's wire, on your screen.PFE· Pfizer Inc.Health Care
